The pricing applies to an underwritten public offering of 10,526,000 shares of its common stock at a price of $1.90 per share. The gross proceeds of the company’s offerings are expected to be approximately $20 million before underwriting discounts, commissions and estimated offering expenses.
EyePoint Pharmaceuticals gave underwriters a 30-day purchase option for up to an additional 1,578,975 shares of common stock at the public offering price.
The closing of the offering is expected to occur April 1 subject to the satisfaction of closing conditions.
More articles on supply chain:
ASC supply chain tip of the day: Clean up inconsistencies
Are you a materials manager or managed by your materials?
SIS named No. 1 ASC EHR vendor for 4th year straight — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.